<DOC>
	<DOCNO>NCT00409838</DOCNO>
	<brief_summary>The purpose study demonstrate clinical efficacy abatacept ( body-weight tiered dose approximate 10 mg/kg ) compare placebo background methotrexate 6 month ( Day 169 ) treatment Korean patient active rheumatoid arthritis inadequate clinical response methotrexate</brief_summary>
	<brief_title>A Phase III Study Abatacept Patients With Rheumatoid Arthritis Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Key Rheumatoid arthritis ( RA ) longer 1 year time initial diagnosis RA Patients must take methotrexate least 3 month least weekly dose 15 mg , stable dose 28 day prior treatment ( Day 1 ) Methotrexate weekly dose low 10 mg permit patient tolerate high dos Key Evidence ( assessed Investigator ) active latent bacterial viral infection time potential enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rheumatoid Arthritis , inadequate response methotrexate</keyword>
</DOC>